REGN - REGENERON PHARMACEUTICALS, INC.
IEX Last Trade
712.87
-2.140 -0.300%
Share volume: 10,865
Last Updated: Fri 27 Dec 2024 08:30:04 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$715.01
-2.14
-0.30%
View ratios
Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
Report Date | 2022-11-03 | 2023-02-06 | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-05 | 2024-05-02 | 2024-08-01 | |
Total revenue | 2.936 B | 3.414 B | 3.162 B | 3.158 B | 3.363 B | 3.434 B | 3.145 B | 3.547 B | |
Cost of revenue | 141.300 M | 302.200 M | 208.400 M | 192.400 M | 224.500 M | 306.800 M | 240.400 M | 257.800 M | |
Gross profit | 2.795 B | 3.112 B | 2.954 B | 2.966 B | 3.138 B | 3.128 B | 2.905 B | 3.289 B | |
11.35% | -5.09% | 0.41% | 5.82% | -0.34% | -7.13% | 13.24% | |||
Operating expenses | 1.440 B | 1.704 B | 1.702 B | 1.737 B | 1.716 B | 1.915 B | 1.937 B | 1.959 B | |
Selling general and admin | 529.100 M | 660.500 M | 601.100 M | 652.000 M | 640.500 M | 737.700 M | 689.000 M | 758.800 M | |
Research and development | 911.300 M | 1.043 B | 1.101 B | 1.085 B | 1.075 B | 1.177 B | 1.248 B | 1.200 B | |
Total expenses | 1.758 B | 2.244 B | 2.160 B | 2.142 B | 2.152 B | 2.432 B | 2.371 B | 2.439 B | |
27.64% | -3.76% | -0.81% | 0.47% | 13.00% | -2.50% | 2.86% | |||
Operating income | 1.178 B | 1.170 B | 1.002 B | 1.016 B | 1.211 B | 1.002 B | 773.800 M | 1.108 B | |
Ebit | 1.224 B | 1.170 B | 1.002 B | 1.016 B | 1.211 B | 1.002 B | 773.800 M | 1.108 B | |
Pretax income | 1.510 B | 1.325 B | 858.000 M | 1.083 B | 1.111 B | 1.148 B | 700.700 M | 1.628 B | |
-12.26% | -35.23% | 26.21% | 2.58% | 3.31% | -38.94% | 132.35% | |||
Income tax | 194.100 M | 127.600 M | 40.200 M | 114.500 M | 103.000 M | -12.000 M | -21.300 M | 195.800 M | |
Net income basic | 1.316 B | 1.197 B | 817.800 M | 968.400 M | 1.008 B | 1.160 B | 722.000 M | 1.432 B | |
-9.01% | -31.68% | 18.42% | 4.07% | 15.06% | -37.74% | 98.38% | |||
Net income | 1.316 B | 1.197 B | 817.800 M | 968.400 M | 1.008 B | 1.160 B | 722.000 M | 1.432 B | |
-9.01% | -31.68% | 18.42% | 4.07% | 15.06% | -37.74% | 98.38% |